INLB (Item 9 Labs) Cyclically Adjusted Revenue per Share: $0.14 (As of Jun. 2023)


INLB Item 9 Labs Corp INLB
12 GF Score
Price $0.00
View Full Analysis

What is Item 9 Labs Cyclically Adjusted Revenue per Share?

Item 9 Labs INLB -99.00% 12 Cyclically Adjusted Revenue per Share is $0.14 as of Jun. 2023. GuruFocus rates INLB with a GF Score™ of 12/100.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Item 9 Labs's adjusted revenue per share for the three months ended in Jun. 2023 was $0.049. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.14 for the trailing ten years ended in Jun. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-08), Item 9 Labs's current stock price is $0.0001. Item 9 Labs's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2023 was $0.14. Item 9 Labs's Cyclically Adjusted PS Ratio of today is 0.00.


Item 9 Labs  (OTCPK:INLB) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Item 9 Labs's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.0001/0.14
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Item 9 Labs Cyclically Adjusted Revenue per Share Related Terms


Item 9 Labs Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Item 9 Labs's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Item 9 Labs Cyclically Adjusted Revenue per Share Chart

Item 9 Labs Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.11 0.11 0.14

Item 9 Labs Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.13 0.14 0.13 0.13 0.14

INLB vs NEPT, CENBF, SGBI: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Item 9 Labs's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Item 9 Labs Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Item 9 Labs's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Item 9 Labs's Cyclically Adjusted PS Ratio falls into.


INLB
12GF Score
Item 9 Labs Corp INLB
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Item 9 Labs Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Item 9 Labs's adjusted Revenue per Share data for the three months ended in Jun. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=0.049/305.1090*305.1090
=0.049

Current CPI (Jun. 2023) = 305.1090.

Item 9 Labs Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201309 0.076 234.149 0.099
201312 0.006 233.049 0.008
201403 0.022 236.293 0.028
201406 0.038 238.343 0.049
201409 0.004 238.031 0.005
201412 0.029 234.812 0.038
201503 0.003 236.119 0.004
201506 0.004 238.638 0.005
201509 -0.001 237.945 -0.001
201512 0.029 236.525 0.037
201603 0.003 238.132 0.004
201606 0.016 241.018 0.020
201609 0.036 241.428 0.045
201612 0.001 241.432 0.001
201703 0.005 243.801 0.006
201706 0.017 244.955 0.021
201709 0.009 246.819 0.011
201712 0.013 246.524 0.016
201803 0.020 249.554 0.024
201806 0.010 251.989 0.012
201809 0.008 252.439 0.010
201812 0.017 251.233 0.021
201903 0.018 254.202 0.022
201906 0.024 256.143 0.029
201909 0.020 256.759 0.024
201912 0.025 256.974 0.030
202003 0.030 258.115 0.035
202006 0.036 257.797 0.043
202009 0.041 260.280 0.048
202012 0.052 260.474 0.061
202103 0.072 264.877 0.083
202106 0.073 271.696 0.082
202109 0.062 274.310 0.069
202112 0.065 278.802 0.071
202203 0.070 287.504 0.074
202206 0.051 296.311 0.053
202209 0.041 296.808 0.042
202212 0.050 296.797 0.051
202303 0.056 301.836 0.057
202306 0.049 305.109 0.049

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $0.14 mean?
Item 9 Labs (INLB) has a Cyclically Adjusted Revenue per Share of $0.14 as of Jun. 2023. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Item 9 Labs and its competitors.
Is Item 9 Labs' Cyclically Adjusted Revenue per Share too high?
Item 9 Labs' current Cyclically Adjusted Revenue per Share is $0.14. Overall, Item 9 Labs has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Item 9 Labs' Cyclically Adjusted Revenue per Share compare to NEPT and CENBF?
Item 9 Labs' Cyclically Adjusted Revenue per Share of $0.14 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Item 9 Labs and its competitors. Item 9 Labs's current Cyclically Adjusted Revenue per Share is $0.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Item 9 Labs stock overvalued right now?
Item 9 Labs (INLB) has a current Cyclically Adjusted Revenue per Share of $0.14. The current Cyclically Adjusted Revenue per Share is $0.14. Item 9 Labs' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Item 9 Labs (INLB), the current Cyclically Adjusted Revenue per Share is $0.14 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Item 9 Labs Business Description

Address 2111 E. Highland Avenue, Suite B375, Phoenix, AZ, USA, 85016
Item 9 Labs Corp is a vertically integrated cannabis operator and dispensary franchisor delivering premium products from its large-scale cultivation and production facilities in the United States. The Item 9 Labs brand specializes in products and user experience across several cannabis categories. The company also offers a dispensary franchise model through the national Unity Rd. retail brand. Easing barriers to entry, the franchise provides an opportunity for both new and existing dispensary owners to leverage the knowledge, resources, and ongoing support needed to thrive in their state compliantly and successfully. It also brings industry practices to markets nationwide through distinctive retail experience, cultivation capabilities, and product innovation.
12GF Score

Get the complete analysis for INLB

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price